Johnson & Johnson's FcRn inhibitor nipocalimab has been awarded fast-track status by the FDA as a treatment for Sjögren's ...

The FDA has granted fast-track designation to nipocalimab for the treatment of Sjögren’s disease, according to a press ...

FDA grants Fast Track designation to Johnson & Johnson’s investigational therapy nipocalimab for the treatment of moderate-to ...

along with the recent definition of disease activity levels and minimal clinically important change, will improve the assessment of patients with primary SS and facilitate the demonstration of ...

Dry eye disease is common but it's not always simple. If eye drops aren't helping, you'll want to see an eye doctor to determine the root cause.

Sjogren’s disease (SjD) is a systemic immune-mediated inflammatory ... with improvements in symptom control, quality of life, time on treatment and survival.21 22 Studies of data collection using ...

Sjogren’s syndrome was suspected based on edentulous state in a middle-aged woman with multisystem involvement. Evaluation with Schirmer’s test, parotid scintigraphy and labial minor salivary gland ...

Johnson & Johnson (NYSE:JNJ) experienced an 11% share price increase over the last quarter, coinciding with pivotal ...

The FDA bestows a Fast Track designation to Johnson & Johnson's nipocalimab for treating moderate-to-severe Sjogren's disease ...

You will be redirected to our submission process. Recent decades have witnessed remarkable strides in the realm of clinical research and treatment for Systemic Lupus Erythematosus (SLE) and Sjögren’s ...

House: Johnson & Johnson has received Fast Track designation (FTD) from the U.S. Food and Drug Administration (FDA) for ...